Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX)
CUSIP: 501976104
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Shares outstanding
- 56,833,213
- Total 13F shares
- 34,131,760
- Share change
- +11,302,004
- Total reported value
- $320,775,226
- Put/Call ratio
- 116%
- Price per share
- $9.40
- Number of holders
- 99
- Value change
- +$111,162,333
- Number of buys
- 61
- Number of sells
- 30
Quarterly Holders Quick Answers
What is CUSIP 501976104?
CUSIP 501976104 identifies KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 501976104:
Top shareholders of KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Westlake BioPartners Fund I, L.P. |
13D/G
3/4/5
|
Dr. Beth C. Seidenberg ("Seidenberg") · 10%+ Owner |
7.8%
|
4,657,257
|
$43,778,216 | $0 | 31 Dec 2025 | |
| Northpond Ventures III, LP |
13D/G
|
Michael P. Rubin |
6.1%
|
3,466,826
|
$28,531,978 | $0 | 31 Dec 2025 | |
| Vida Ventures Advisors, LLC |
13F
|
Company |
8%
|
4,523,924
|
$27,143,544 | — | 30 Sep 2025 | |
| Bain Capital Life Sciences Opportunities III, LP |
13D/G
|
— |
5.4%
|
3,110,000
|
$25,595,300 | $0 | 31 Dec 2025 | |
| GILEAD SCIENCES, INC. |
13F
3/4/5
|
Company · 10%+ Owner |
7.3%
|
4,126,119
|
$24,756,714 | — | 30 Sep 2025 | |
| GordonMD Global Investments LP |
13D/G
|
— |
7%
|
3,058,485
|
$23,275,071 | $0 | 13 Nov 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
5.9%
|
3,368,370
|
$20,210,220 | — | 30 Sep 2025 | |
| Fred E. Cohen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,605,909
mixed-class rows
|
$9,580,576 | — | 29 May 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.7%
|
1,512,199
|
$9,074,000 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.3%
|
1,322,625
|
$7,935,750 | — | 30 Sep 2025 | |
| Beth C. Seidenberg |
3/4/5
|
Director |
—
mixed-class rows
|
951,302
mixed-class rows
|
$6,650,121 | +$999,998 | 18 Dec 2025 | |
| Westlake BioPartners Opportunity Fund I, L.P. |
3/4/5
|
10%+ Owner |
1.5%
|
869,317
|
$6,519,877 | +$999,998 | 18 Dec 2025 | |
| Insight Holdings Group, LLC |
13F
|
Company |
1.7%
|
989,054
|
$5,934,324 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.2%
|
677,587
|
$4,065,522 | — | 30 Sep 2025 | |
| MBB PUBLIC MARKETS I LLC |
13F
|
Company |
1.1%
|
614,477
|
$3,686,862 | — | 30 Sep 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
1%
|
586,909
|
$3,521,454 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.97%
|
551,635
|
$3,309,810 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.85%
|
482,054
|
$2,892,324 | — | 30 Sep 2025 | |
| Kera Capital Partners, Inc. |
13F
|
Company |
0.74%
|
421,924
|
$2,531,544 | — | 30 Sep 2025 | |
| Peapod Lane Capital LLC |
13F
|
Company |
0.56%
|
318,760
|
$1,912,199 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.49%
|
278,329
|
$1,670,347 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.44%
|
252,212
|
$1,513,272 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.36%
|
202,690
|
$1,216,140 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.35%
|
198,851
|
$1,193,106 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.31%
|
174,900
|
$1,049,400 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.31%
|
174,203
|
$1,045,218 | — | 30 Sep 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.29%
|
164,796
|
$988,776 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.29%
|
164,614
|
$987,684 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.28%
|
157,422
|
$944,532 | — | 30 Sep 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.26%
|
147,712
|
$886,272 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.23%
|
132,451
|
$794,706 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
125,578
|
$753,468 | — | 30 Sep 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.18%
|
103,808
|
$622,848 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.16%
|
91,300
|
$547,800 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.14%
|
81,300
|
$487,800 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.13%
|
76,191
|
$457,146 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.11%
|
64,964
|
$389,784 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.09%
|
51,678
|
$310,068 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.09%
|
49,107
|
$294,642 | — | 30 Sep 2025 | |
| Karen Marie Walker |
3/4/5
|
Chief Technology Officer |
—
mixed-class rows
|
108,501
mixed-class rows
|
$276,159 | -$292,776 | 15 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.08%
|
43,132
|
$258,792 | — | 30 Sep 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.07%
|
38,821
|
$232,926 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.06%
|
36,691
|
$220,146 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.06%
|
34,022
|
$204,132 | — | 30 Sep 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.01%
|
7,500
|
$195,000 | — | 30 Sep 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.06%
|
32,205
|
$193,230 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.05%
|
27,176
|
$163,056 | — | 30 Sep 2025 | |
| CAXTON CORP |
13F
|
Company |
0.04%
|
22,981
|
$137,887 | — | 30 Sep 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.04%
|
20,446
|
$122,676 | — | 30 Sep 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
19,438
|
$116,628 | — | 30 Sep 2025 |
Institutional Holders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) as of Q4 2025
As of 31 Dec 2025,
Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) was held by
99 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,131,760 shares.
The largest 10 holders included
GordonMD Global Investments LP, GILEAD SCIENCES, INC., Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, ADAGE CAPITAL PARTNERS GP, L.L.C., AIGH Capital Management LLC, MORGAN STANLEY, and Insight Holdings Group, LLC.
This page lists
99
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
74
Q4 2025 holders
99
Holder diff
25
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.